Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa

Journal of Medical Virology

Volumn 83, Issue 10, 2011, Pages 1764-1769

  van Zyl, Gert U ^a,b   van der Merwe, Lize ^c,d   Claassen, Mathilda ^a,b   Zeier, Michele ^a,e   Preiser, Wolfgang ^a,b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^e STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Antiretroviral drug resistance; Etravirine associated mutations; HIV 1 subtype C; Nevirapine; Thymidine analog mutations

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS RESISTANCE; CROSS-SECTIONAL STUDY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; SOUTH AFRICA; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; NEVIRAPINE; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SOUTH AFRICA; TREATMENT FAILURE; VIRAL LOAD; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80051589041     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22189     Document Type: Article

References (28)

1. Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, Hoepelman AI. 2008. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: Evidence of transmitted resistance in rural South Africa. AIDS 22: 2210-2212.
2. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M, Wainberg MA. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17: F1-F5.
3. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, Wainberg MA. 2006. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20: F9-F13.
4. Coutsinos D, Invernizzi CF, Xu H, Moisi D, Oliveira M, Brenner BG, Wainberg MA. 2009. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 83: 2029-2033.
5. Coutsinos D, Invernizzi CF, Xu H, Brenner BG, Wainberg MA. 2010. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antivir Chem Chemother 20: 117-131.
6. Di Vincenzo P, Rusconi S, Adorni F, Vitiello P, Maggiolo F, Francisci D, Di Biagio A, Monno L, Antinori A, Boeri E, Punzi G, Perno CF, Callegaro A, Bruzzone B, Zazzi M. 2010. Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA). HIV Med 11: 530-534.
7. Doualla-Bell F, Gaseitsiwe S, Ndungu T, Modukanele M, Peter T, Novitsky V, Ndwapi N, Tendani G, Avalos A, Wester W, Bussmann H, Cardiello P, Marlink R, Moffat H, Thior I, Wainberg MA, Essex M. 2004. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir Chem Chemother 15: 189-200.
8. Doualla-Bell F, Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S, Oliveira M, Moisi D, Ndwapi N, Moffat H, Essex M, Wainberg MA. 2006. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 50: 4182-4185.
9. Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson RE, Fielding KL, Churchyard GJ, Morris L, Grant AD. 2009. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 49: 1928-1935.
10. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, Fiscus SA, Nelson JA, Eron JJ, Kumwenda J. 2009. The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23: 1127-1134.
11. Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wainberg MA. 2009. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis 200: 1202-1206.
12. Kiertiburanakul S, Wiboonchutikul S, Sukasem C, Chantratita W, Sungkanuparph S. 2010. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. J Clin Virol 47: 330-334.
13. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. 2009. Differences in resistance mutations among HIV-1 non-subtype B infections: A systematic review of evidence (1996-2008). J Int AIDS Soc 12: 11.
14. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, Thabane L, Wilson K, Guyatt GH, Bangsberg DR. 2006. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA 296: 679-690.
15. Minzi OM, Naazneen AS. 2008. Validation of self-report and hospital pill count using unannounced home pill count as methods for determination of adherence to antiretroviral therapy. Tanzan J Health Res 10: 84-88.
16. Munerato P, Sucupira MC, Oliveros MP, Janini LM, de Souza DF, Pereira AA, Inocencio LA, Diaz RS. 2010. HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of Sao Paulo, Brazil. AIDS Res Hum Retrovir 26: 265-273.
17. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, Wood R. 2007. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 12: 83-88.
18. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. 2009. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 14: 523-531.
19. Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, Petropoulos CJ, Deeks SG, Kuritzkes DR. 2009. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 83: 2038-2043.
20. Poveda E, Anta L, Blanco JL, Perez-Elias MJ, Garcia F, Leal M, Ribera E, Gutierrez F, Soriano V, de Mendoza C. 2010. Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. AIDS 24: 469-471.
21. Stevens WS, Wallis CL, Sanne I, Venter F. 2009. Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa? J Acquir Immune Defic Syndr 52: 655-656.
22. Taiwo B, Chaplin B, Penugonda S, Meloni S, Akanmu S, Gashau W, Idoko J, Adewole I, Murphy R, Kanki P. 2010. Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. Curr HIV Res 8: 194-198.
23. Turner D, Brenner BG, Routy JP, Petrella M, Wainberg MA. 2004. Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol 27: 31-39.
24. Turner D, Shahar E, Katchman E, Kedem E, Matus N, Katzir M, Hassoun G, Pollack S, Kessner R, Wainberg MA, Avidor B. 2009. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel. J Med Virol 81: 1509-1512.
25. van Zyl GU, van der Merwe L, Claassen M, Cotton MF, Rabie H, Prozesky HW, Preiser W. 2009. Protease inhibitor resistance in South African children with virologic failure. Pediatr Infect Dis J 28: 1125-1127.
26. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, de Bethune MP, De Smedt G, Woodfall B, Picchio G. 2010. Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 24: 503-514.
27. Wainberg MA. 2009. Two standards of care for HIV: Why are Africans being short-changed? Retrovirology 6: 109.
28. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. 2010. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 53: 480-484.